Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio

Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio
Aerpio Pharmaceuticals announced a licensing agreement with Gossamer Bio to develop and commercialize Aerpio’s investigative therapy AKB-4924 as a treatment for inflammatory bowel disease (IBD). AKB-4924 (to be changed to GB004) is a hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer. It works by blocking the prolyl-hydroxylase (PHD) enzymes, helping to stabilize HIF-1 alpha — a master regulator of the cellular response to hypoxia,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *